Shares of Spruce Biosciences, Inc. (SPRB) are rising more than 100% Friday morning after the company announced partnership with Japan's Kaken Pharmaceutical to develop Spruce's investigational drug, tildacerfont, for the treatment of congenial adrenal hyperplasia (CAH).
As per the deal, Spruce will receive an upfront payment of $15 million, with additional milestone payments on achieving targets. Spruce is also entitled to get double-digit royalties on net sales in Japan.
"As a specialty pharmaceutical company with a strong presence in Japan, Kaken is the ideal strategic partner for the territory, and supports Spruce's partnering strategy to develop tildacerfont in markets outside of the United States," said Javier Szwarcberg, Chief Executive Officer of Spruce Biosciences.
SPRB, currently at $2.68, has traded in the range of $0.95-$4.18 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.